l

The content of this website is intended for healthcare professionals only

Statins safe for rheumatoid arthritis patients

Patients with rheumatoid arthritis are likely to experience the same level of cardiovascular benefits as other individuals

Ingrid Torjesen

Tuesday, 16 April 2019

Patients with rheumatoid arthritis are likely to experience the same level of cardiovascular benefits from statins as other individuals, without additional risks, show results from a large clinical trial*, published in Arthritis & Rheumatology.

Patients with rheumatoid arthritis have an approximately 50% higher risk of experiencing cardiovascular events such as heart attack and stroke compared with the general population, but it's unclear how safe and effective statins are for patients with inflammatory conditions such as rheumatoid arthritis.


To investigate researchers designed the Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients with Rheumatoid Arthritis (TRACE RA), a multi-centre, randomised, double-blind trial comparing the statin atorvastatin with placebo.

The trial included 3,002 patients with rheumatoid arthritis who were over aged 50 years or had rheumatoid arthritis for more than 10 years, without clinical atherosclerosis, diabetes, or myopathy. Patients were randomised to receive atorvastatin 40mg daily or placebo.

During a median follow-up of 2.5 years, 1.6% of patients who received atorvastatin and 2.4% of patients receiving placebo experienced cardiovascular death, heart attack, stroke, transient ischemic attack, or any arterial revascularization. After adjustments, there was a 40% lower risk of cardiovascular events for patients taking atorvastatin, although the difference was not statistically significant because the overall rate of events was low.

At the end of the trial, patients taking atorvastatin had significantly lower LDL cholesterol as well as significantly lower levels of C-reactive protein, a marker of inflammation, compared with patients taking placebo. Adverse events in the atorvastatin and placebo groups were similar.

One of the researchers Professor Deborah Symmons of the University of Manchester said: "The trial found that the statin reduced levels of cholesterol by similar amounts as has been seen in other populations studied. The results also show that it is as safe for patients with rheumatoid arthritis to take statins as for the general population.”

She added: “In addition, because of the low overall rate of cardiovascular events in the trial population, there is no indication for all patients with rheumatoid arthritis to be prescribed a statin. This is unlike diabetes where the great majority of patients are recommended to take a statin."

The study authors recommend that patients with rheumatoid arthritis be prescribed statins according to national or local guidelines for managing cardiovascular risk in the general population.


*Kitas GD, Nightingale P, Armitage J, et al. Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial. Arthritis & Rheumatology. First published: 15 April 2019. DOI:10.1002/art.40892

Registered in England and Wales. Reg No. 2530185. c/o Wilmington plc, 5th Floor, 10 Whitechapel High Street, London E1 8QS. Reg No. 30158470